|Bid||174.6400 x 400|
|Ask||174.7200 x 400|
|Day's Range||174.2001 - 176.1490|
|52 Week Range||154.2500 - 193.3100|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.44%|
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.
The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...
This year has been a year to watch the US economy. Hopes for change, tax reform, and industry-friendly policies drove the markets (SPY) higher.
According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.
In 1928, Congress passed a joint resolution establishing Child Health Day, the express purpose of which was to raise awareness “of the fundamental necessity of a year-round program to protect and develop ...
Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16.
The Health Care Select Sector SPDR (NYSEArca: XLV ) , the largest healthcare exchange traded fund, is up nearly 3% over the past week as the second-best-performing sector in the S&P 500 this year continues ...
The healthcare sector, the third-largest sector weight in the S&P 500, is one of the legitimate leadership groups in the U.S. this year. In fact, healthcare trails only technology in terms of year-to-date ...
Johnson & Johnson (JNJ) reported ~2% growth in its top line to $18.8 billion in 2Q17, compared with $18.5 billion in 2Q16. The company surpassed analysts’ EPS (earnings-per-share) estimate of of…
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
The US Specialized therapeutics business includes products from various therapeutic areas including eye care, medical aesthetics including skin care, facial aesthetics, plastic surgery and other products, ...
In 2Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.5 billion, which represented a ~1% year-over-year decline and a ~24% quarter-over-quarter rise.
Bristol-Myers Squibb's (BMY) immunoscience business is represented by the drug Orencia. Let's take a look at Orencia's revenue over the last few quarters.
GE's Healthcare segment remained a top performer in 2Q17. Revenue-wise, this segment remained the third-largest contributor to GE’s total operating revenue of $28.0 billion.